<DOC>
	<DOCNO>NCT00026338</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Biological therapy erlotinib use different way stimulate immune system stop cancer cell grow . Combining chemotherapy biological therapy may kill tumor cell . It yet know gemcitabine effective without erlotinib treat pancreatic cancer . PURPOSE : Randomized phase III trial determine effectiveness gemcitabine without erlotinib treat patient unresectable locally advanced metastatic pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine With Without Erlotinib Treating Patients With Unresectable Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival rate patient unresectable locally advanced metastatic pancreatic cancer treat gemcitabine without erlotinib . - Compare progression-free survival rate patient treat regimen . - Compare quality life patient treat regimen . - Compare response rate response duration patient treat regimen . - Compare nature , severity , frequency toxic effect regimens patient . - Correlate expression tissue epidermal growth factor receptor level diagnosis outcome response patient treat regimen . - Determine pharmacokinetics erlotinib patient . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord participate center , extent disease ( locally advance vs metastatic ) , ECOG performance status ( 0-1 v 2 ) . Patients randomize one two treatment arm . - Arm I : Patients receive gemcitabine IV 30 minute day 1 , 8 , 15 , 22 , 29 , 36 , 43 course 1 , last 8 week , day 1 , 8 , 15 subsequent course , last 4 week . Patients also receive 1 2 dos oral erlotinib daily . - Arm II : Patients receive gemcitabine arm I 1 2 dos oral placebo daily . Treatment continue arm absence disease progression unacceptable toxicity . Quality life assess baseline , day 29 course 1 , day 1 subsequent course , 4 week study , every 12 week disease progression . Patients follow 4 week every 12 week thereafter . PROJECTED ACCRUAL : A total 800 patient ( 400 per treatment arm ) accrue study within 11 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma pancreas Locally advance metastatic disease consider unresectable No known CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin le 2 time upper limit normal ( ULN ) AST and/or ALT le 2 time ULN ( 5 time ULN liver metastasis present ) Renal : Creatinine le 1.5 time ULN Cardiovascular : No uncontrolled high blood pressure No unstable angina No congestive heart failure No myocardial infarction within past year No cardiac ventricular arrhythmia require medication Gastrointestinal : No gastrointestinal ( GI ) tract disease result inability take oral medication uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease ulcerative colitis ) No postsurgical malabsorption characterize : Uncontrolled diarrhea result weight loss vitamin deficiency OR Requires IV hyperalimentation Pancreatic enzyme supplementation allow provide criterion meet Ophthalmic : No ocular inflammation infection unless fully treat prior study No significant ophthalmologic abnormality , include follow : Severe dry eye syndrome Sjogren 's syndrome Keratoconjunctivitis sicca Severe exposure keratopathy Disorders would increase risk epitheliumrelated complication ( e.g. , bullous keratopathy , aniridia , severe chemical burn , neutrophilic keratitis ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No serious active infection No serious underlie medical , psychological , geographical condition would preclude study participation No prior allergic reaction compound similar chemical biologic composition erlotinib No prior malignancy within past 5 year except cancer situ basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy immunotherapy Chemotherapy : No prior chemotherapy except fluorouracil ( without leucovorin calcium ) gemcitabine administer concurrently radiotherapy radiosensitizer No concurrent cytotoxic chemotherapy Endocrine therapy : Not specify Radiotherapy : See Chemotherapy At least 4 week since prior radiotherapy recover Prior radiotherapy local disease allow evidence disease progression occur No concurrent radiotherapy Surgery : See Disease Characteristics At least 2 week since prior major surgery No concurrent ophthalmic surgery Other : No prior epidermal growth factor receptor inhibitor At least 2 week since prior investigational drug No concurrent investigational drug least 30 day study No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>